The authors reply

Affiliations

¹ Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK.
² National Registry of Rare Kidney Diseases, Bristol, UK.
³ Health Economics and Outcomes Research (HEOR), Novartis Pharma AG, Basel, Switzerland.
⁴ National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
⁵ Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK. Electronic address: d.gale@ucl.ac.uk.

Katie Wong et al. Kidney Int. 2026 Jan.

. 2026 Jan;109(1):225-226.

doi: 10.1016/j.kint.2025.08.036.

¹ Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK.
² National Registry of Rare Kidney Diseases, Bristol, UK.
³ Health Economics and Outcomes Research (HEOR), Novartis Pharma AG, Basel, Switzerland.
⁴ National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
⁵ Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK. Electronic address: d.gale@ucl.ac.uk.

No abstract available

Publication types